The Dose-Response Relationship of Peginterferon Alfa-2a and Ribavirin in the Treatment of Patients Coinfected with HIV-HCV

REFERENCES

• Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–1374.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Bhagani S, Benhamou Y et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. 2008;9: 82–88.
   PubMed Web of Science ®Google Scholar
• Soriano V, Puoti M, Sulkowski M et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007;21:1073–1089.
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438–450.
   PubMed Web of Science ®Google Scholar
• Garret F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839–2848.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Torres M, Slim J, Bhatti L, et al. Standard ver-sus high dose ribavirin in combination with peginterferon alfa-2a (40KD) in genotype 1 (G1) HCV patients coinfected with HIV: final results of the PARADIGM study [abstract 1561]. Hepatology. 2009;50:1022A–1023A.
   Google Scholar
• McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061–1069.
   PubMed Web of Science ®Google Scholar
• Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treat-ment. Clin Gastroenterol Hepatol. 2007;5:124–129.
   PubMed Web of Science ®Google Scholar
• Snoeck E, Wade JR, Duff F, Lamb M, Jorga K. Predicting sustained virological response and anaemia in chronic hep-atitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol. 2006;62:699–709.
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroen-terology. 2007;132:103–112.
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982.
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginter-feron-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008;135:451–458.
   PubMed Web of Science ®Google Scholar
• Vogel M, Rockstroh J. Highlights of the third international workshop on HIV and hepatitis coinfection. Expert Rev Anti Infect Ther 2007;5:769–771.
   PubMedGoogle Scholar
• Nunez M, Miralles C, Berdun MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retro viruses. 2007;23:972–982.
   PubMed Web of Science ®Google Scholar
• Conjeevaram HS, Fried MW, Jeffers L et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroen-terology. 2006;131:470–477.
   PubMed Web of Science ®Google Scholar
• Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kD) and ribavirin for black Ameri-can patients with chronic HCV genotype 1. Hepatology. 2004;39:1702–1708.
   PubMed Web of Science ®Google Scholar
• Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265–2271.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Torres M, Jeffers LJ, Sheikh MY et al. Peginter-feron alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med. 2009;360:257–267.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Brown RS, Jr., McCone J et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology. 2007;46:982–990.
   PubMed Web of Science ®Google Scholar
• Chung R, Umbleja T, Butt A, et al. SLAM-C (ACTG A5178): Role of early virologic response in extended therapy with PEG-interferon and weight-based ribavirin in HCV/HIV co-infection. Presented at: 16th Conference on Retrovi-ruses and Opportunistic Infections; February 8–11, 2009; Montreal. Abstract 103LB.
   Google Scholar
• Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology. 2003;37:1343–1350.
   PubMed Web of Science ®Google Scholar
• Ge D, FeIlay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clear-ance. Nature. 2009;461:399–401.
   PubMed Web of Science ®Google Scholar
• Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treat-ment in HIV-infected persons. J Viral Hepatol. 2006;13: 683–689.
   PubMed Web of Science ®Google Scholar
• Brau N, Rodriguez-Torres M, Prokupek D, et al. Treatment of chronic hepatitis C in HIV/HCV-coinfection with inter-feron alpha-2b+ full-course vs. 16-week delayed ribavirin. Hepatology. 2004;39:989–998.
   PubMed Web of Science ®Google Scholar